Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
| Autor: | Daniel J. Wallace, Michelle Petri, Murat Inanc, Ronald F van Vollenhoven, Ben Parker, Sasha Bernatsky, Dafna D. Gladman, Juanita Romero-Diaz, Barri J. Fessler, Rachelle Donn, Gunnar Sturfelt, Kristjan Steinsson, Diane L. Kamen, Meggan Mackay, Asad Zoma, Graciela S. Alarcón, Caroline Gordon, Anisur Rahman, Ann E. Clarke, Paul R. Fortin, Christine A. Peschken, Ian N. Bruce, Ola Nived, John G. Hanly, Ellen M. Ginzler, Murray B. Urowitz, Rosalind Ramsey-Goldman, Manuel Ramos-Casals, S. Sam Lim, Kenneth C. Kalunian, Guillermo Ruiz-Irastorza, Mary Anne Dooley, Mark Lunt, David A. Isenberg, Joan T. Merrill, Munther A. Khamashta, Susan Manzi, Cynthia Aranow, Jorge Sanchez-Guerrero, Sang Cheol Bae |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Kidney Disease Disease Comorbidity Cardiovascular Cohort Studies 0302 clinical medicine immune system diseases Cardiovascular Disease Prevalence Immunology and Allergy Lupus Erythematosus Systemic 030212 general & internal medicine skin and connective tissue diseases Metabolic Syndrome Systemic lupus erythematosus Middle Aged Connective tissue disease 3. Good health Phenotype 6.1 Pharmaceuticals Cohort Public Health and Health Services Female medicine.drug Cohort study Adult medicine.medical_specialty Clinical Sciences Immunology Lupus Systemic Lupus Erythematosus Autoimmune Disease General Biochemistry Genetics and Molecular Biology 03 medical and health sciences Young Adult Rheumatology Clinical Research Internal medicine medicine Humans Rheumatology and Autoimmunity 030203 arthritis & rheumatology Inflammation Lupus Erythematosus business.industry Prevention Inflammatory and immune system Systemic Hydroxychloroquine Clinical and Epidemiological Research medicine.disease Arthritis & Rheumatology Logistic Models Metabolic syndrome business |
| Zdroj: | Annals of the rheumatic diseases, vol 74, iss 8 Annals of the Rheumatic Diseases Annals of the Rheumatic Diseases; 74(8), pp 1530-1536 (2015) Europe PubMed Central |
| ISSN: | 1468-2060 |
| Popis: | Background The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE. Methods Recently diagnosed (< 15 months) patients with SLE from 30 centres across 11 countries were enrolled into the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort from 2000 onwards. Baseline and annual assessments recorded clinical, laboratory and therapeutic data. A longitudinal analysis of factors associated with MetS in the first 2 years of follow-up was performed using random effects logistic regression. Results We studied 1150 patients with a mean (SD) age of 34.9 (13.6) years and disease duration at enrolment of 24.2 (18.0) weeks. In those with complete data, MetS prevalence was 38.2% at enrolment, 34.8% at year 1 and 35.4% at year 2. In a multivariable random effects model that included data from all visits, prior MetS status, baseline renal disease, SLICC Damage Index > 1, higher disease activity, increasing age and Hispanic or Black African race/ethnicity were independently associated with MetS over the first 2 years of follow-up in the cohort. Conclusions MetS is a persistent phenotype in a significant proportion of patients with SLE. Renal lupus, active inflammatory disease and damage are SLE-related factors that drive MetS development while antimalarial agents appear to be protective from early in the disease course. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|